LEUCOMAX LAUNCH IN UK
Schering-Plough and Sandoz Phar-maceuticals have announced the UK launch of Leucomax (molgramostim), a granulocyte macrophage colony stimulating factor, for use in combination with cancer chemotherapy.
The UK is the first European Community country to approve the product since its recommendation for approval in September by the EC's Committee for Proprietary Medicinal Products. The product was developed jointly by Sandoz and Schering, and is to be marketed jointly in the EC by the two companies.
A similar product, filgrastim (G-CSF), is already on the market, but as yet there have been no direct clinical comparisons. Therefore, says John Scarffe, consultant at Christie Hospital, UK, cost will play an important part in the choice of treatment - the drugs are similar in price.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze